Free Trial
→ Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX (From InvestorPlace) (Ad)tc pixel
NASDAQ:BIVI

BioVie Q1 2026 Earnings Report

BioVie logo
$1.65 -0.07 (-4.07%)
Closing price 05/5/2026 03:59 PM Eastern
Extended Trading
$1.68 +0.04 (+2.12%)
As of 05/5/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

BioVie EPS Results

Actual EPS
-$0.98
Consensus EPS
-$0.79
Beat/Miss
Missed by -$0.19
One Year Ago EPS
N/A

BioVie Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioVie Announcement Details

Quarter
Q1 2026
Date
11/10/2025
Time
Before Market Opens
Conference Call Date
Monday, November 10, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

BioVie's Q3 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q3 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

BioVie's Q1 2026 Quarterly ReportQuarterly Report
(10-Q)

BioVie Earnings Headlines

BioVie advances long COVID trial, top-line data expected by summer
May 4 at 8:39 PM  |  finance.yahoo.comhttps://finance.yahoo.com/video/biovie-advances-long-covid-trial-152456713.html
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3281541/0/en/biovie-to-host-virtual-kol-event-to-discuss-the-phase-2-study-of-bezisterim-for-the-treatment-of-parkinson-s-disease-ahead-of-topline-data-in-2q26-on-may-7-2026.html
Revealed: The World’s First Trillion-Dollar Robot
Jensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar robot. But there's one thing Nvidia can't do alone. A virtually unknown $7 company holds the technology Nvidia needs to make that vision a reality. Analyst Michael Robinson - who called Nvidia at $0.80 and Bitcoin at $300 - has identified this stock as his next potential winner, with nearly 20 prior calls returning 1,000% or more.tc pixel
 |  Weiss Ratings (Ad)
BioVie abstract on Parkinson’s drug accepted for neurology conference
April 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/biovie-abstract-parkinson-drug-accepted-091000392.html
BioVie abstract on Parkinson's drug accepted for neurology conference
April 14, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1090519?snapi
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273252/0/en/biovie-announces-abstract-accepted-for-presentation-at-the-2026-american-academy-of-neurology-annual-meeting.html
See More BioVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email.

About BioVie

BioVie (NASDAQ:BIVI) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease. BIV201 is being assessed for its potential to reduce ammonia levels and improve cognitive function, with data from early studies indicating a favorable safety profile and signs of clinical benefit.

In addition to its lead program, BioVie maintains exploratory efforts targeting other chronic liver indications, including primary biliary cholangitis and alcohol‐associated liver disease. These preclinical and early‐stage candidates leverage the company’s expertise in small‐molecule modulation of metabolic and inflammatory pathways, with the goal of expanding treatment options for patients who currently have limited therapeutic choices.

Headquartered in Emeryville, California, BioVie was founded with the mission of transforming the management of liver diseases through innovative drug development. The company operates in collaboration with leading academic institutions and clinical research organizations across the United States and Canada. Guided by an experienced executive team with backgrounds in biotechnology and pharmaceutical development, BioVie is committed to advancing its portfolio toward late‐stage clinical trials and eventual regulatory approval.

View BioVie Profile
Earnings Tools